Stéphane Laurent: Key Highlights of ISBT 2026 for INLOG
Stéphane Laurent, International Sales Director at INLOG, Consultant -Advisor at ADEN Developpement-Consulting Healthcare, shared a post on LinkedIn:
“Key Highlights of International Society of Blood Transfusion (ISBT) 2026 Kuala Lumpur for INLOG
Strengthening INLOG’s international position as a leading provider of Blood Donor Management and Blood Establishment Information Systems (BBIS).
Showcasing the complete EdgeBlood, Blood Donor Online (BDO) and EdgeCell portfolio to the global transfusion medicine community.
Meeting national Blood Services, Ministries of Health, Red Cross organizations and major hospitals from across the world.
Accelerating expansion across ASEAN, with a particular focus on Malaysia, Indonesia, Thailand, Vietnam, Singapore and the Philippines.
Developing strategic distribution partnerships with leading regional healthcare technology companies.
Exploring long-term collaborations with IVD, automation and medical device manufacturers to deliver integrated solutions.
Promoting INLOG’s 20-year experience alongside the French Blood Establishment (EFS) as a benchmark for digital transformation in transfusion medicine.
Demonstrating end-to-end digital management covering donor recruitment, collection, testing, processing, inventory, distribution, traceability and haemovigilance.
Highlighting INLOG’s expertise beyond blood management with cells, tissues, organs, cord blood and human milk bank management through EdgeCell.
Presenting innovative digital donor engagement solutions, including online donor questionnaires, appointment scheduling and donor communication.
Discussing interoperability, cybersecurity, cloud architectures, AI opportunities and international standards with healthcare partners.
International Society of Blood Transfusion (ISBT) is not only where the transfusion community meets—it is where the future of Blood Donor
Management is designed together.”
Stay updated with Hemostasis Today.
-
Nov 11, 2026, 15:42Tareq Abadl: The Clinical Impact of Kell Alloimmunization
-
Nov 11, 2026, 15:30Alejandro González Veliz: Does PCI Change The Long-Term Outcome In Stable Coronary Artery Disease?
-
Nov 11, 2026, 15:25Preparing for the SoHO Regulation – EBA Board Convenes in Vienna – European Blood Alliance
-
Nov 11, 2026, 15:20Vaidehi Prasanth: IV Iron in Heart Failure – Exploring Hospitalisation Benefits vs. Infection Risk in Open Heart
-
Nov 11, 2026, 15:18Stefan Prendić: Can Algorithms Support Antibody Identification in Immunohematology?
-
Nov 11, 2026, 15:12Perioperative Challenges in Hemophilia Patients on Rebalancing Therapies
-
Nov 11, 2026, 15:03Maria Elisa Mancuso: World-Renowned Faculty and 33 Global Participants Unite at Hemophilia Academy 2026
-
Nov 11, 2026, 15:01Hassan Raza: The JAK2 V617F Revolution
-
Nov 11, 2026, 14:57Edward Lee Carter: Factor Xla Inhibition Enters Clinical Practice – FDA Approval of Asundexian